Clinical trials: Ophthalmic Solutions
Allergic Conjunctivitis
Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
The purpose of this study is to evaluate the effectiveness and safety of Olopatadine Hydrochloride (HCl) ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese…
- Trial name
- NCT02251613
- Testing
- Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05%
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension…
- Trial name
- NCT04620135
- Testing
- Netarsudil ophthalmic solution 0.02%, Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
- Where
- Japan
- Volunteers
- 245 people
- Sponsor
- Aerie Pharmaceuticals
Hyperemia Eye
Safety and Tolerability of PRO-185
Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events.
- Trial name
- PRO-185 (NCT05470868)
- Testing
- Naphazoline / Hypromellose Ophthalmic
- Where
- Mexico
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Disease
A Study Designed to Evaluate Tear Production
The purpose of this study is to evaluate tear production following acute administration of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) in subjects with dry eye disease (DED).
- Trial name
- NCT06544707
- Testing
- 0.003% AR-15512 ophthalmic solution
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis
This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.
- Trial name
- NCT05733624
- Testing
- SCAI-001 0.01% eyedrop, SCAI-001 0.02% eyedrop, Restasis 0.05% eyedrop
- Where
- 11 sites in South Korea
- Volunteers
- 116 people
- Sponsor
- SCAI Therapeutics
Myopia
Myopia Control With Novel Eye Drops
Myopia currently affects 30% of the world and by 2050, almost 50% of the world will be myopic based on conservative estimates.1 In 2050, this will equate to almost 5 billion people with myopia, and those with high myopia will…
- Trial name
- NCT04301323
- Testing
- BHVI1 eye drops, BHVI2 eye drops, BHVI3 eye drops
- Where
- Vietnam
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Hai Yen Eye Care
Dry Eye
Evaluation of BTV100 in Subjects With Dry Eye Disease
This study will be a randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study to evaluate the efficacy, safety and tolerability of repeat dosing of Cevimeline Ophthalmic Solution compared to the vehicle…
- Trial name
- NCT06543303
- Testing
- BTV100 Low dose, BTV100 Mid dose, BTV100 High dose
- Where
- 6 sites in Australia, Taiwan
- Volunteers
- 123 people
- Sponsor
- BioTheraVision, Inc.
Neovascular Age Related Macular Degeneration
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and efficacy of topical ophthalmic squalamine lactate eye drops in treating patients with neovascular age-related macular degeneration (wet AMD), a degenerative retinal eye…
- Trial name
- NCT01678963
- Testing
- Squalamine lactate, Vehicle control
- Where
- 20 sites in United States
- Volunteers
- 142 people
- Sponsor
- Ohr Pharmaceutical Inc.
Dry Eye Disease
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease
A Randomized, Double-Masked, Vehicle-Controlled Parallel Group Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT06389214
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Eye Dryness
Clinical Trial for the Evaluation of Safety and Efficacy of Drop 0.4%
The aim of the trial is to compare the safety and efficacy of the moisturizing solution DROP 0.4% with the moisturizing solution AVIZOR EYE DROPS 0.2% PRESERVED in relieving the symptoms of dry eye over one month of use.
- Trial name
- DROP04 (NCT06985875)
- Testing
- Multidose mosturizing solution DROP 0.4%, Multidose mosturizing solution Avizor Eye Drops 0.2% Preserved
- Volunteers
- 79 people
- Sponsor
- Avizor SA
Cataract
Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
Compare ocular tissue levels following topical ocular instillation of 1.5% levofloxacin ophthalmic solution or an active comparator in subjects undergoing cataract surgery.
- Trial name
- NCT00630019
- Testing
- 1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Santen Inc.
Ocular Hypertension, Open-Angle Glaucoma
The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma
The objective of this study is to investigate corneal confocal microscopic findings, ocular signs and symptoms in patients on treatment with the preserved prostaglandin analogue latanoprost 0.005% eye drops (Xalatan®) and after…
- Trial name
- NCT01369771
- Testing
- Tafluprost 0.0015%
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- FinnMedi Oy
Corneal Neovascularization
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
The first stage of this study will evaluates the tolerability of different concentrations of Conbercept eye drop to patients with corneal neovascularization.
- Trial name
- NCT04215393
- Testing
- Conbercept eye drop
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Dry Eye Disease
Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.
- Trial name
- NCT02831387
- Testing
- P-321 Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Parion Sciences
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Nuclear Cataract
Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract
This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract
- Trial name
- NCT00825721
- Testing
- LiquiTears, C-KAD Ophthalmic Solution
- Where
- Nepal
- Volunteers
- 81 people
- Sponsor
- Chakshu Research, Inc.
Allergic Rhinitis, Allergic Conjunctivitis
The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo
The primary objective of this study is to assess the relative efficacy of Ectoin® Allergy Eye Drops and Ectoine® Allergy Nasal Spray compared to placebo, by evaluating Total Nasal Symptom Score (TNSS) and Total Ocular Symptom…
- Trial name
- PPL-003 (NCT01471184)
- Testing
- Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- Bitop AG
Dry Eye
An Evaluation of the Nighttime Retention of Effect of an Investigational Lubricant Eye Drop (FID 115958D)
The purpose of this study is to describe the night-time use of an investigational lubricant eye drop.
- Trial name
- NCT01165164
- Testing
- FID 115958D (lubricant eye drop)
- Volunteers
- 89 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd.
- Trial name
- NCT07661329
- Testing
- Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)
- Where
- 22 sites in United States, India
- Volunteers
- 600 people
- Sponsor
- YS Life Science Co., Ltd.
Neurotrophic Keratitis
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.
- Trial name
- NCT07568730
- Testing
- Lacripep, Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- TearSolutions, Inc.